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Background: Effective therapies for early endometrial cancer usually involve surgical excision and consequent
infertility Therefore, new treatment approaches that preserve fertility should be developed. Metformin, a well-tolerated
anti-diabetic drug, can inhibit cancer cell growth. However, the mechanism of metformin action is not well understood.
Here we investigate the roles of autophagy and apoptosis in the anti-cancer effects of metformin on endometrial
cancer cells.
Methods: Ishikawa endometrial cancer cells were treated with metformin. WST-8 assays, colony formation assays,
flow cytometry, caspase luminescence measurement, immunofluorescence, and western blots were used to assess
the effects of metformin on cell viability, proliferation, cell cycle progression, apoptosis, and autophagy.
Results: Metformin-treated cells exhibited significantly lower viability and proliferation and significantly more cell
cycle arrest in G1 and G2/M than control cells. These cells also exhibited significantly more apoptosis via both
intrinsic and extrinsic pathways. In addition, metformin treatment induced autophagy. Inhibition of autophagy,
either by Beclin1 knockdown or by 3-methyladenine-mediated inhibition of caspase-3/7, suppressed the anti-proliferative
effects of metformin on endometrial cancer cells. These findings indicate that the anti-proliferative effects and
apoptosis caused by metformin are partially or completely dependent on autophagy.
Conclusions: We showed that metformin suppresses endometrial cancer cell growth via cell cycle arrest and
concomitant autophagy and apoptosis.
Keywords: Metformin, Endometrial cancer, Autophagy, ApoptosisBackground
Endometrial cancer is one of the most common gyneco-
logic malignancies in the United States [1], and its inci-
dence is rapidly increasing in Japan [2]. Approximately
80% of endometrial cancers are diagnosed at an early
stage and are completely cured with hysterectomy [3,4].
In addition, approximately 25% of all cases are diagnosed
in premenopausal women, and 3%–14% of all cases are
diagnosed before 40 years of age [5-8]. Endometrial can-
cer in young women poses a therapeutic dilemma be-
cause preservation of fertility is often a major concern.
Progesterone and medroxyprogesterone acetate are often* Correspondence: akimasat@belle.shiga-med.ac.jp
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unless otherwise stated.used to treat endometrial cancers in patients who desire
to preserve their fertility [9]. Some younger women with
endometrial cancer present with obesity, irregular menses,
chronic anovulation, polycystic ovarian syndrome, insulin
resistance, type 2 diabetes mellitus, or a combination [7,10].
Elimination of such conditions using low-dose cyclic pro-
gestin may decrease recurrence or de novo development of
endometrial cancer. However, maintenance treatment with
progestin prohibits pregnancy, and the therapeutic effect of
progestin in endometrial cancers appears to be inadequate.
Therefore, new approaches to the treatment and prevention
of endometrial cancer must be developed for women trying
to conceive.
The biguanide drug metformin is among the most pre-
scribed drug for the treatment of type 2 diabetes worldwide.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tolerated drug that has numerous cellular effects in mul-
tiple tissues. The main anti-hyperglycemic effect is believed
to be due to the suppression of hepatic glucose production
[11]. In addition, metformin has been reported to inhibit
the growth of various cancers [12-18], including endomet-
rial cancer [19]. Metformin activates AMPK, a critical cellu-
lar energy sensor. Activation of AMPK suppresses the
mTOR; this cascade leads to reduced protein synthesis and
cell proliferation [20]. In addition, higher doses of metfor-
min (2–5 mM) reportedly induce apoptosis in endometrial
cancer cell lines [20]. Whether metformin induces other
forms of cell death such as autophagy is unknown.
Programmed cell death refers to any type of cell death
mediated by an intracellular program [21]. Apoptosis is
type-I programmed cell death, which is morphologically
characterized by cell shrinkage, chromatin condensation,
nuclear fragmentation, and formation of apoptotic bodies.
Autophagic cell death is type-II programmed cell death,
which is characterized by the accumulation of multi-
lamellar vesicles that engulf the cytoplasm and organelles
[22]. Apoptosis has long been known to play an important
role in the response to several chemotherapeutic agents;
however, the importance of treatment-induced autophagic
cell death in tumor regression has only recently been rec-
ognized [23,24]. Metformin induces apoptosis in some
cancers [12,14,25] and autophagy in other, including mel-
anoma, lymphoma, and colon cancer [12,17,18]. Multiple
functional relationships between apoptosis and autophagy
in cancer cells have been reported. Thus, a better un-
derstanding of the interactions between apoptosis and
autophagy may be a key to continued improvement of
cancer treatments.
Here we used an endometrial cancer cell line to inves-
tigate the anti-cancer activity of metformin. We focused
on the role of autophagy and its effects on apoptotic cell
death.
Methods
Reagents and antibodies
Metformin (1,1-dimethylbiguanide hydrochloride), 3-
methyladenine (3MA), chloroquine (CQ), and siRNA were
purchased from Sigma Aldrich (St. Louis, MI, USA). Anti-
actin antibody was purchased from Sigma; all other anti-
bodies were purchased from Cell Signaling Technology
(Beverly, MA, USA). Modified Eagle’s medium (MEM),
non-essential amino acids (NEAA), and trypsin/EDTA
(0.25% trypsin, 1 mM EDTA) were purchased from Wako
Pure Chemical Industries (Osaka, Japan). Antibiotics/anti-
mycotics (ABAM) were purchased from Gibco (Carlsbad,
CA, USA). Cell counting kit-8 (CCK-8) was purchased
from Dojindo Laboratories (Tokyo, Japan). Caspase-Glo
assay kits were purchased from Promega (Madison, WI,
USA). FITC Annexin V apoptosis detection kit I, FITCBrdU Flow Kit, and BD MitoScreen (JC-1) were pur-
chased from BD Pharmingen (San Diego, CA, USA).
Acridine orange (AO) was purchased from Molecular
Probes (Eugene, OR, USA). Lipofectamine 2000 was
purchased from Invitrogen (Carlsbad, CA, USA).Cell culture, cell viability assay, and colony formation assay
The Ishikawa human endometrial adenocarcinoma cell
line was purchased from the European Collection of Cell
Culture (ECACC, Salisbury, UK). Ishikawa cells were cul-
tured in MEM supplemented with l-glutamine (2 mM), 5%
(v/v) FBS, 1% NEAA, and ABAM at 37°C in a humidified
atmosphere with 5% CO2.
We performed this work by using only cell line, but not
clinical samples. Therefore, this work has been granted ex-
emption from the Ethics Committee of Shiga University of
Medical Science.
The WST-8 assay was used to measure cell viability.
Cells were plated on 96-well plates at a density of 1 ×
104 cells/well in 100 μL medium. At 24 h after seeding,
metformin (0, 0.01, 1, 5, 10, or 20 mM) was added to
each well and cells were cultured for an additional 48 h.
CCK-8 solution (10 μL) was then added to each well,
and the plates were incubated at 37°C for 2 h. The ab-
sorbance of WST-8 formazan was measured at 450 nm
using a microplate reader.
To measure colony formation, adherent Ishikawa cells
were trypsinized and 1000 viable cells (depending on
the experiment) were subcultured in 60-mm plates; each
treatment was tested in triplicate. After 24 h, the medium
was replaced with fresh culture medium containing met-
formin (0, 0.01, 1, 5, 10, or 20 mM) in a 37°C humidified
atmosphere with 95% air and 5% CO2 and grown for
2 weeks. The culture medium was replaced every 3 days.
Cell clones were stained for 15 min with a solution con-
taining 0.5% crystal violet and 25% methanol in water.
Stained cells were rinsed three times with tap water to
remove excess dye. Each dish was then washed and
dried, and the number of colonies/plate was macroscop-
ically counted. Colonies were defined as those contai-
ning >50 cells by microscopic examination.Assessment of cell cycle, apoptosis, and mitochondrial
membrane potential via flow cytometry
To assess cell cycle progression, cells were seeded onto
60-mm plates and incubated for 24 h to allow for expo-
nential growth. Ishikawa cells were incubated with or
without metformin for an additional 48 h. All cells were
incubated with 10 μM BrdU (BD Pharmingen) for
30 min; BrdU-labeled cells were then harvested, fixed,
permeabilized, and stained with FITC-conjugated anti-
BrdU antibody and 7-AAD, according to the manufac-
turer’s instructions. A flow cytometer (BD, FACSCalibur,
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and cell cycle phase.
Annexin V-FITC apoptosis detection kits were used
according to the manufacturer’s instructions to measure
apoptosis. Cells were incubated with or without metfor-
min for 48 h, collected and washed with PBS, gently re-
suspended in annexin V binding buffer, and incubated
with annexin V-FITC/7-AAD. Flow cytometry was per-
formed using CellQuest Pro software (BD).
A mitochondrial membrane potential detection kit was
used according to the manufacturer’s instructions to
measure mitochondrial membrane potential (Δψm). In
brief, cells were treated with or without metformin, re-
suspended in 0.5 mL of JC-1 solution, and incubated at
37°C for 15 min. Cells were then rinsed before flow cy-
tometry. A dot plot of red (living cells with intact Δψm)
versus green fluorescence (cells lacking Δψm) was gener-
ated. Data were expressed as the percentage of cells with
intact Δψm.
Caspase activity
The Caspase-Glo™ 3/7, Caspase-Glo™ 8 or Caspase-Glo™
9 assay kit was used according to the manufacturer’s in-
structions to measure the activity of caspase 3/7, caspase-
8 or caspase-9, respectively. In brief, 50 μL of cell lysate
(cytosolic extracts, 20 μg) was incubated in 50 μL of
Caspase-Glo reagent at room temperature for 1 h.
After incubation, the luminescence of each sample was
measured in a plate-reading luminometer (Tecan, Linz,
Austria).
Detection and quantification of autophagic cells by
staining with acridine orange
To identify autophagic cells, the volume of the cellular
acidic compartment was visualized by AO staining [26].
Cells were seeded in 60-mm culture dishes and treated
as described above. After 48 h of treatment with or with-
out metformin, cells were incubated with medium con-
taining 5 μg/mL AO for 15 min. The AO medium was
then removed, cells were washed once with PBS, and
fresh medium was added. Fluorescence micrographs
were taken using an Olympus inverted fluorescence micro-
scope (Olympus Corp., Tokyo, Japan). All images presented
are at the same magnification. Flow cytometry was used to
determine the number of cells with acidic vesicular or-
ganelles (AVOs). Cells were trypsinized and harvested;
BD FACSCalibur and BD CellQuest Pro software was used
to analyze the cells. A minimum of 10,000 cells within the
gated region was analyzed for each treatment.
RNA interference
Lipofectamine 2000 reagent and the Invitrogen protocol
were used to introduce Beclin-1 siRNA (Sigma-Aldrich;
seq1 #SASI_Hs02_00336256) or a scramble controlsiRNA sequence (Sigma-Aldrich; #SIC001) into Ishikawa
cells. Cells were then incubated for 48 h prior to metfor-
min treatment (0, 5, or 10 mM).
Western blot analysis
Ishikawa cells (2 × 106/dish) were seeded in 100-mm cul-
ture dishes and cultured for 24 h. After metformin treat-
ment, cells were lysed in RIPA lysis buffer containing a
protease-inhibitor cocktail (“Complete” protease inhibi-
tor mixture; Roche Applied Science, Indianapolis, IN) on
ice for 30 min. Suspensions of lysed cells were centrifuged
at 14 000 × g at 4°C for 10 min; supernatants containing
soluble cellular proteins were collected and stored at −80°C
until use. BCA protein assay kits were used to measure
protein concentration. Furthermore, 15 μg of protein was
resuspended in sample buffer and separated on a 4%–20%
tris-glycine gradient gel using the SDS-PAGE system. Re-
solved proteins were transferred to PVDF membrane,
which was blocked with 5% milk in tris-buffered saline/
0.1% Tween 20. Immunodetection was performed using
each primary antibody. The membranes were incubated
with donkey anti-rabbit horseradish peroxidase (HRP)-
conjugated secondary antibody (1:5000 dilution). The
ECL Western Blotting Detection System (GE Health-
care, Little Chalfont, UK) was used to detect signals,
which were visualized using a LAS-4000 mini (GE
Healthcare). Actin was used as the loading control.
Statistical analysis
All data points represent the mean of at least three inde-
pendent measurements and are expressed as the mean ±
standard deviation. SPSS ver. 20 was used to perform
one-way ANOVA and Tukey’s post hoc test or Student’s
t-test, as appropriate. A significance threshold of p < 0.05
was used.
Results
Metformin inhibits growth of Ishikawa endometrial
cancer cells
WST-8 and colony formation assays were used to assess
the effects of metformin on the viability of Ishikawa
endometrial cancer cells. The number of viable cells de-
creased with increasing concentrations of metformin for
24- or 48-h treatments (Figure 1A). After 24 h, 20 mM
of metformin significantly reduced the number of viable
cells but 0.01–10 mM metformin did not. After 48 h,
metformin at 5 mM or more significantly reduced the
number of viable cells. At 48 h, IC50 of metformin was
6.78 mM.
The ability of metformin-treated and control Ishikawa
cells to form colonies on 60-mm culture plates within
two weeks was examined. Metformin at concentrations
as low as 1 mM, significantly reduced colony formation
(Figure 1B), and the inhibitory effect of metformin on
AB
Figure 1 Metformin inhibits Ishikawa cell growth and induces cell death. (A) WST-8 assays were used to measure the viability of Ishikawa
cells after treatment with metformin (0, 0.1, 1, 5, 10, or 20 mM) for 24 or 48 h. (B) Colony formation assays were used to measure the colonogenicity
of Ishikawa cells after metformin treatment. The number of untreated cells was set as 100%. The data are mean values from triplicate experiments.
*p < 0.05, **p < 0.01, one way ANOVA, post hoc comparisons, Tukey’s test. Columns, mean; error bars, SD.
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5 mM or more reduced colony formation to 10% of that
of untreated control cells. Based on these results and those
in several published reports [13,17,27,28], 5 or 10 mM
metformin was used in the following experiments.
Metformin induces cell cycle arrest and modulates cell
cycle proteins in Ishikawa endometrial cancer cells
To investigate the underlying mechanisms of metformin-
induced growth inhibition in Ishikawa cells, we first
evaluated the effect of metformin on cell proliferation
and cell-cycle progression. Cell-cycle profiles were analyzed
after 48 h of metformin treatment. There were significantly
fewer S-phase cells and significantly more G2/M cells in
metformin-treated cultures compared with those in
control cultures, and these effects were dose dependent
(Figure 2A). Furthermore, we used western blots to as-
sess the effects of metformin on the expression of two cell
cycle regulators, p53 and p21 (Figure 2B). Expression of
p53 decreased in a dose-dependent manner with metformin
treatment (Figure 2C). The induction of p21, a cell-cycle
blocker, increased in a dose-dependent manner with met-
formin treatment (Figure 2D). These results indicate thatmetformin induced p21 expression, which led to cell cycle
arrest in G1 and G2/M via a p53-independent pathway.
Metformin induces apoptosis of Ishikawa endometrial
cancer cells via intrinsic and extrinsic pathways
To assess whether the induction of apoptosis also contrib-
uted to metformin-mediated inhibition of Ishikawa cell
growth, the proportion of apoptotic cells was measured.
After cells were incubated with or without metformin
(5 or 10 mM) for 48 h, the proportion of apoptotic cells
was measured by flow cytometric of annexin V expression
and JC-1 staining, which indicates the presence of a mito-
chondrial membrane potential (Figure 3A and 3B). Our
results demonstrate that the proportion of apoptotic cells
was higher in metformin-treated cultures compared with
that in controls.
To understand the mechanism by which metformin
induced apoptosis in Ishikawa cells, we examined pro-
apoptotic activity. Apoptosis can be activated through two
main pathways: the intrinsic mitochondria-dependent
pathway and the extrinsic death-receptor-dependent path-
way. Caspase-8 is predominantly activated by signals from
the extrinsic death-receptor pathway, while caspase-9
A B
C D
Figure 2 Metformin induces cell cycle arrest. (A) Ishikawa cells were treated with metformin (0, 5, or 10 mM) for 48 h. After fixation, the cell
cycle was analyzed by flow cytometry. Quantitative analysis of percentage gated cells at the G0/G1, S, and G2/M phases are shown. Data are
shown as mean ± SD of three independent replicate measurements. *p < 0.05 and **p < 0.01 vs. untreated cells. (B) Ishikawa cells were treated
with metformin (0, 0.1, 1, 5, or 10 mM) for 48 h. Cell lysates were separated by SDS-PAGE and analyzed on western blots with the indicated antibodies.
Actin was used as a loading control. One representative experiment of three experiments is shown. (C and D) Densitometric quantitation of p21/actin and
p53/actin protein expression levels is shown as fold changes. One representative experiment of three is shown. *p < 0.05 and **p < 0.01 vs. untreated cells.
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chondrial pathway. Together, pro-apoptotic Bax and anti-
apoptotic Bcl-2 play an important role in mitochondrial
outer membrane permeabilization. Metformin treatment
induced a marked, dose-dependent increase in the Bax/
Bcl-2 ratio (Figure 3D). Furthermore, metformin-mediated
apoptotic death was accompanied by the activation of cas-
pase, which is the principal apoptosis-executing enzyme.
Fluorescence calorimetric analysis demonstrated that met-
formin treatment induced the activation of caspase-3/7, -8,
and -9 (Figure 3E). Consistent with the induction of apop-
tosis, western blots revealed that metformin treatment led
to cleavage of caspase-3 and PARP in Ishikawa cells in a
dose-dependent manner (Figure 3C).
Metformin triggers autophagy in Ishikawa cells
To determine whether metformin induced autophagy in
Ishikawa cells, we used AO to stain AVOs, including au-
tophagic vacuoles. Untreated Ishikawa cells exhibited
bright green fluorescence in the cytoplasm and nuclei andlacked bright red fluorescence. In contrast, metformin-
treated cells exhibited AVOs, identified as bright red
compartments (Figure 4A). The number of AVOs was
significantly higher in metformin-treated cells compared
with that in untreated controls, and this effect was dose
dependent (Figure 4A). Levels of LC3B (an autophago-
some component) and p62 (an autophagosome target)
positively and negatively correlate with autophagy, re-
spectively. Therefore, we used western blots to assess
LC3B-I to LC3B-II conversion and p62 protein levels.
As expected, metformin treatment induced significant
LC3 I to II conversion (Figure 4C and D) and a decrease
in p62 levels (Figure 4C and E) in a dose-dependent
manner. Taken together, these results demonstrate that
metformin induced autophagy in Ishikawa cells.
Inhibition of autophagy reduced metformin-induced
apoptosis in Ishikawa cells
To determine the relationship between apoptosis and au-
tophagy in Ishikawa cells, we inhibited autophagy either
AC
E
D
B
Figure 3 (See legend on next page.)
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Figure 3 Metformin induces apoptosis in Ishikawa cells. (A) Ishikawa cells were treated with metformin (0, 5, or 10 mM) for 48 h. Cells
were harvested and stained with annexin V-FITC and 7-AAD, and cell apoptosis was analyzed using flow cytometry. *p < 0.05 and **p < 0.01 vs.
untreated cells. (B) Ishikawa cells were treated with metformin (0, 5, or 10 mM) for 48 h, stained with JC-1, incubated, and analyzed using flow
cytometry. *p < 0.05 and **p < 0.01 vs. untreated cells. (C and D) Ishikawa cells were treated with metformin (0, 0.1, 1, 5, or 10 mM) for 48 h. Cell
lysates were separated by SDS-PAGE and analyzed on western blots probed with the indicated antibodies. Actin was used as a loading control.
Densitometric quantitation of Bax/Bcl-2 protein expression ratios are shown as fold changes. One representative experiment of three is shown.
(E) Ishikawa cells were incubated with metformin (0, 5, or 10 mM) for 48 h, followed by assays of caspase-3/7, -8, and -9 activity. *p < 0.05 and
**p < 0.01 vs. untreated cells.
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assessed the effects on metformin-mediated apoptosis. A
WST-8 assay showed that 3MA and CQ treatment sig-
nificantly enhanced the viability of metformin-treated
(10 mM) cells (Figure 5A). On addition, flow cytometric
analysis showed that 3MA treatment caused a marked
decrease in the proportion of metformin-treated (10 mM)
apoptotic cells (Figure 5B). Moreover, 3MA treatment
caused a significant reduction in caspase activity in
metformin-treated (10 mM) cells (Figure 5C). Thus, these
findings revealed that inhibition of metformin-mediated
autophagy reduced apoptosis in Ishikawa cells.
To confirm these results, we used siRNA to repress ex-
pression of the autophagy regulator Beclin1 in Ishikawa
cells. Beclin1 siRNA knocked down Beclin1 expression by
approximately 75% (Figure 6A). Upon metformin treat-
ment, significantly fewer Annexin-V-positive cells were
observed in Beclin1siRNA cells compared with that in
controls (Figure 6B). The inhibition of autophagy by
Beclin1 siRNA resulted in decreases in caspase-3/7 activ-
ity (Figure 6C), PARP cleavage, and LC3-II and increases
in p62 (Figure 6D), as did pharmacologic inhibition of au-
tophagy by 3MA (Figure 5D). These results demonstrate
that the inhibition of autophagy reduced apoptosis associ-
ated with metformin treatment.
Discussion
Recent data indicate that metformin may be a useful
anti-proliferation agent for some types of cancer. The
potential role of metformin in treating endometrial can-
cer has been explored in a number of in vitro studies
[19,29,30]. However, the anti-tumor effects of metformin
are not completely understood. Furthermore, the effect
of metformin on autophagy has not been investigated in
endometrial cancer cells. Here we demonstrate that met-
formin induced caspase-dependent apoptosis and sup-
pressed proliferation by upregulating the cyclin-dependent
kinase inhibitor p21 and inducing both G1 and G2/M
arrest. In addition, we revealed that metformin pro-
moted the formation of AVOs, the conversion of LC3-I
to LC3-II, and the degradation of p62. Moreover, both
pharmaco logic and genetic inhibition of autophagy re-
duced metformin-induced apoptosis. To the best of our
knowledge, this is the first report to demonstrate thatmetformin induces autophagy and that autophagy and
apoptosis are linked processes.
Several studies have indicated that metformin treatment
decreases cancer cell viability by inducing apoptosis. Can-
trell et al. showed that metformin increased activation of
caspase-3 in human endometrial cancer cells in a dose-
dependent manner [19]. Hanna et al. suggested that met-
formin induces apoptosis [20]. Similar to the results of
these studies, we observed that metformin treatment of
Ishikawa endometrial cancer cells induces a significant in-
crease in apoptosis in a dose-dependent manner.
To elucidate the mechanism of metformin-induced
apoptosis, we investigated mitochondrial function and
caspase activity in Ishikawa cells. We observed that met-
formin treatment altered the expression of Bcl-2 family
proteins, PARP cleavage, and the activation of caspase-3/
7, -8, and -9. Caspase-8 is essential for death-receptor-
mediated apoptosis, while caspase-9 is essential for
mitochondria-mediated apoptosis. These 2 pathways
converge on caspase-3/7 activation, leading to subsequent
activation of other caspases. Our results are similar to
those of previous findings demonstrating that metformin
induces significant increases in apoptosis in pancreatic cell
lines and that metformin-induced apoptosis is associated
with PARP cleavage, which is dependent on activation of
caspase-3, -8, and -9 [14]. Thus, metformin may modulate
apoptotic cell death via extrinsic and intrinsic pathways in
Ishikawa cells.
In addition, metformin has been shown to induce ar-
rest of the cell cycle in cancer cell lines [31]. Cantrell
et al. showed that metformin induces G0/G1 cell cycle
arrest in Ishikawa cells [19]. However, we observed that
metformin blocked cell cycle progression not only in
G0/G1 but also in the G2/M phase. This apparent dis-
crepancy may result from differences in incubation time,
pharmacologic dose or both. G0/G1 cell cycle arrest re-
sulted from a 24-h incubation [19], and G0/G1 and G2/
M phase arrest resulted from a 48-h incubation. These
findings suggest that metformin may block the cell cycle
at two points. We observed that the cyclin-dependent
kinase inhibitor p21, which plays an important role in
cell-cycle arrest, was activated by metformin. Notably,
p21 is among the genes most consistently induced by
metformin [32]. Recent reports indicate that p21 is not
AB
D E
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Figure 4 Metformin triggers autophagy in Ishikawa cells. (A) Ishikawa cells were incubated with metformin (0, 0.1, 1, 5, or 10 mM) for 48 h.
The presence of acridine orange-stained intracellular vesicles was demonstrated by fluorescent microscopy (lower panel) and flow cytometry,
showing an increase in red fluorescence (FL3) intensity (upper panel). (B) Autophagy was quantified by measuring the percentage of cells with
bright red fluorescence (FL3-positive cells; data are presented as the mean ± SD of three independent measurements, *p < 0.05). (C) Immunoblot
analysis of LC3 conversion and p62 levels in Ishikawa cells treated with metformin (0, 0.1, 1, 5, or 10 mM). (D and E) Densitometric quantitation of
LC3B-II/LC3B-I and p62/actin protein expression ratios are shown as fold changes. *p < 0.05 and **p < 0.01 vs. untreated cells.
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transition but also an inhibitor of the CDK1/cyclin B
complex that maintains G2/M arrest [33,34]. These re-
ports support our supposition that the G2/M phase cell
cycle block occurs at 48 h.
Alternatively, it is possible that low doses of metformin
cause G0/G1 arrest, whereas higher doses cause G2/M ar-
rest. High metformin concentrations induce more p21 ex-
pression; therefore, they may induce apoptosis of cells not
only in G0/G1 but also in the G2/M cell cycle arrest.
Moreover, p21 expression is induced by both p53-
dependent and -independent mechanisms. Mutations in
the p53 gene are reportedly evident in >50% of all
known cancer types. These mutations are recognized as
one of the major events in carcinogenesis, and the Ishi-
kawa cell line also has a p53 mutation [35]. Therefore,
agents that induce p21 expression through a p53-A B
C
Figure 5 Pharmacologic inhibition of autophagy reduces metformin-m
96-well plates and incubated with the indicated dose of metformin (with o
assays. Data are presented as the mean ± SD of three independent replicat
(B) Flow cytometry of apoptosis in Ishikawa cells treated with metformin (with
(C) Ishikawa cells were incubated with the indicated dose of metformin alone
caspase-3/7 activity. *p < 0.05 and **p < 0.01 vs. 3MA untreated cells. (D) Ishika
48 h, and cell lysates were subjected to western blot analysis using antibodiesindependent pathway may have potential as candidate
drugs. Histone deacetylase (HDAC) inhibitors, such as
Psammaplin A, suppress cell proliferation and induce
apoptosis in Ishikawa cells via p53-independent upregu-
lation of p21 expression [36]. Our results indicate that
metformin treatment of Ishikawa cells increased p21 ex-
pression but also decreased mutant p53 expression.
These findings also indicate that metformin-induced p21
expression may be regulated through a p53-independent
mechanism. Therefore, we propose that metformin in-
duces cell-cycle arrest in Ishikawa endometrial cancer cells
both at G0/G1 and G2/M by activating p21 via a p53-
independent pathway.
Autophagy is a process where the cytosol and organelles
become encased in vacuoles called autophagosomes. Al-
though autophagy is primarily a protective process for
the cell, it can play a role in cell death [37]. Therefore,D
ediated apoptotic cell death. (A) Ishikawa cells were seeded in
r without 3MA or CQ) for 48 h; cell viability was determined by WST-8
e measurements. *p < 0.05 and **p < 0.01 vs. 3MA or CQ untreated cells.
or without 3MA) for 48 h. *p < 0.05 and **p < 0.01 vs. 3MA untreated cells.
or combined with 3MA for 48 h. Cells were then lysed to measure
wa cells were treated with the indicated dose of metformin (±3MA) for
against LC3B, p62, and cleaved PARP. Actin was used as a loading control.
AC D
B
Figure 6 Genetic inhibition of autophagy reduces metformin-mediated apoptotic cell death. (A) Western blot analysis of Beclin1
expression in siBeclin1 and control Ishikawa cells. (B) Beclin1 expression was blocked in Ishikawa cells by Beclin1 siRNA; cells were incubated with
the indicated concentrations of metformin for 48 h. Cells were then harvested and analyzed by flow cytometry. *p < 0.05 and **p < 0.01 vs.
Control siRNA cells. (C) Beclin1 siRNA Ishikawa cells were incubated with the indicated concentrations of metformin for 48 h. Cells were then
lysed to measure caspase-3/7 activity. *p < 0.05 and **p < 0.01 vs. Control siRNA cells. (D) Beclin1, LC3B, p62, and cleaved PARP expression were
examined in siBeclin1-treated and control cells. Actin expression was used as a loading control.
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recent work highlights the prosurvival role of autophagy
in cancer cells [38]. Alternatively, autophagy may confer
a disadvantage on cancer cells [12]. The variability in
the effects of autophagy on cancer cells may depend on
the cell type, cell cycle phase, genetic background, and
microenvironment [39]. When the autophagic capacity
of cancer cells is reached, apoptosis is promoted [40].
This finding is particularly interesting because metfor-
min can induce autophagy in colon cancer and melan-
oma [12,17], as well as Ishikawa endometrial cancer
cells, as demonstrated here.
Metformin induced apoptosis and autophagy in Ishikawa
endometrial cells. Because autophagy has been implicated
in the promotion and inhibition of cell survival [21], we
were interested in the role of autophagy in metformin-
mediated apoptosis. To determine whether the processes ofautophagy and apoptosis are linked, we performed several
experiments following the inhibition or induction of au-
tophagy. We observed that both pharmacologic and genetic
inhibition of autophagy promoted cancer cell survival and
reduced metformin-induced apoptosis. In addition, our re-
sults show that inhibition of autophagy decreased the cleav-
age of PARP (Figure 5D and 6D) and the activation of
caspase-3/7, -8, and -9 (data not shown). These findings in-
dicate that inhibitors of autophagy enhanced both intrinsic
and extrinsic activation of apoptosis. Taken together, these
data suggest that metformin induces autophagic cell death
in Ishikawa endometrial cancer cells. To the best of our
knowledge, this is the first demonstration that metfor-
min promotes the elimination of endometrial cancer
cells through concomitant regulation of autophagy and
apoptosis. These results are based on in vitro studies
only, and further in vivo studies are necessary.
Takahashi et al. Cancer Cell International 2014, 14:53 Page 11 of 12
http://www.cancerci.com/content/14/1/53Conclusions
We demonstrate that metformin is cytotoxic to Ishikawa
endometrial cancer cells. Several mechanisms underlying
the anti-tumor effects of metformin in Ishikawa cells are
revealed by the data presented here. Metformin was
shown to inhibit Ishikawa endometrial cancer cell prolif-
eration through the induction of cell cycle arrest and
caspase-dependent apoptosis and enhanced autophagic
flux. In addition, we showed that pharmacological or
genetic inhibition of autophagy decreased metformin-
induced apoptotic cell death. These observations indi-
cate that metformin may be a promising agent for the
treatment of early endometrial cancer. In addition, our
findings may provide insight into the role of autophagy
in anti-cancer therapies.
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